Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVSNASDAQ:CTMXNASDAQ:MISTNASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$4.03+6.6%$3.42$1.75▼$10.00$274.72M0.67734,213 shs806,566 shsCTMXCytomX Therapeutics$2.51-5.3%$1.18$0.40▼$2.82$202.36M1.112.15 million shs3.12 million shsMISTMilestone Pharmaceuticals$1.73+6.8%$1.14$0.63▼$2.75$92.49M0.86906,444 shs968,758 shsOGIOrganigram$1.31-3.0%$1.14$0.85▼$2.08$180.74M1.35663,484 shs467,510 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals+6.05%+15.47%+11.33%+0.75%+86.57%CTMXCytomX Therapeutics-0.40%+12.56%+212.97%+284.50%+47.65%MISTMilestone Pharmaceuticals+6.46%+12.34%+32.06%+5.49%+15.33%OGIOrganigram-0.89%-4.38%+13.91%+19.09%-23.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRVSCorvus Pharmaceuticals2.2295 of 5 stars3.51.00.00.02.42.50.6CTMXCytomX Therapeutics4.4742 of 5 stars3.52.00.04.73.42.51.3MISTMilestone Pharmaceuticals3.0547 of 5 stars3.25.00.00.03.52.50.0OGIOrganigram0.8233 of 5 stars0.03.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 3.00Buy$15.00272.21% UpsideCTMXCytomX Therapeutics 3.00Buy$5.33112.48% UpsideMISTMilestone Pharmaceuticals 2.40Hold$17.00882.66% UpsideOGIOrganigram 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MIST, OGI, CTMX, and CRVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/15/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.005/15/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.005/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.504/1/2025MISTMilestone PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.79 per shareN/ACTMXCytomX Therapeutics$147.56M1.37N/AN/A($0.71) per share-3.54MISTMilestone Pharmaceuticals$1M92.49N/AN/A$0.50 per share3.46OGIOrganigram$194.09M0.90N/AN/A$1.83 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%8/5/2025 (Estimated)CTMXCytomX Therapeutics-$570K$0.4814.76N/AN/A10.96%-41.47%8.11%8/14/2025 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$0.78N/AN/AN/AN/A-151.82%-49.85%8/14/2025 (Estimated)OGIOrganigram-$33.39M$0.10N/AN/AN/A-31.69%-8.59%-6.54%8/12/2025 (Estimated)Latest MIST, OGI, CTMX, and CRVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 million5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/A3/6/2025Q4 2024CTMXCytomX Therapeutics-$0.23$0.22+$0.45$0.22$13.53 million$38.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A0.920.92CTMXCytomX TherapeuticsN/A1.041.04MISTMilestone Pharmaceuticals2.1815.4015.40OGIOrganigramN/A3.361.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%CTMXCytomX Therapeutics67.77%MISTMilestone Pharmaceuticals86.18%OGIOrganigram34.63%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals28.50%CTMXCytomX Therapeutics7.00%MISTMilestone Pharmaceuticals19.50%OGIOrganigram0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3068.17 million44.15 millionOptionableCTMXCytomX Therapeutics17080.62 million72.78 millionOptionableMISTMilestone Pharmaceuticals3053.46 million48.05 millionOptionableOGIOrganigram860133.88 million126.10 millionOptionableMIST, OGI, CTMX, and CRVS HeadlinesRecent News About These CompaniesJune 2025 Watchlist: Best Canadian Cannabis Stocks for GrowthMay 31 at 10:00 AM | marijuanastocks.comTidal Investments LLC Sells 225,184 Shares of Organigram Holdings Inc. (NASDAQ:OGI)May 24, 2025 | marketbeat.comOrganigram (NASDAQ:OGI) Releases Earnings Results, Misses Expectations By $0.10 EPSMay 14, 2025 | marketbeat.comEarnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%May 14, 2025 | uk.investing.comOrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)May 12, 2025 | zacks.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comInsights Ahead: OrganiGram Holdings's Quarterly EarningsMay 9, 2025 | benzinga.comOrganigram (OGI) to Release Earnings on MondayMay 7, 2025 | marketbeat.comOrganigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export AwardsMay 5, 2025 | finance.yahoo.comOrganigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export AwardsMay 5, 2025 | businesswire.comOrganigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025May 2, 2025 | businesswire.comOrganigram Global’s Products Recognized at the CNB AwardsApril 24, 2025 | finance.yahoo.comOrganigram Global's Products Recognized at the CNB AwardsApril 24, 2025 | businesswire.comOrganigram Global Shares Recording of its OG Investor SessionApril 22, 2025 | businesswire.comOrganigram Global Announces Acquisition Of Collective Project Limited - Quick FactsApril 3, 2025 | nasdaq.comOrganigram Global Inc. (OGI.TO)April 2, 2025 | ca.finance.yahoo.comOrganigram Global to Host the OG Investor Session, its Inaugural Virtual Event for Investors, and Announcement of Name Change on TSX and NASDAQApril 2, 2025 | businesswire.comOrganigram acquires Collective Project for C$6.2MApril 2, 2025 | markets.businessinsider.comTop 5 cannabis stocks with operations in CanadaApril 1, 2025 | msn.comStocks in play: Organigram Global Inc.April 1, 2025 | ca.finance.yahoo.comOrganigram Enters U.S. Through Acquisition of Collective Project BeveragesApril 1, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?3 Tech Leaders Announce Buybacks Totaling $85 BillionBy Leo Miller | May 5, 2025View 3 Tech Leaders Announce Buybacks Totaling $85 BillionAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernDon’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeMIST, OGI, CTMX, and CRVS Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$4.03 +0.25 (+6.61%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$4.04 +0.01 (+0.37%) As of 09:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.CytomX Therapeutics NASDAQ:CTMX$2.51 -0.14 (-5.28%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$2.55 +0.04 (+1.55%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Milestone Pharmaceuticals NASDAQ:MIST$1.73 +0.11 (+6.79%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$1.73 +0.00 (+0.06%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Organigram NASDAQ:OGI$1.31 -0.04 (-2.96%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$1.34 +0.03 (+2.29%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
